.
Mark S. Sulkowski, MD, reviews data on new nucleosides, nonnucleosides, and PIs that may offer options for the treatment of patients with HCV. (9 minutes)
http://www.clinicaloptions.com/
,
.
Daniel Shouval, MD, reviews selected abstracts on the treatment of hepatitis B presented at this annual international meeting. (17 minutes)
http://www.clinicaloptions.com/
,
..
Also at *CCO
Michael P. Manns, MD, reviews data presented at this important annual meeting that elucidate evolving knowledge about standard of care therapy.
(9 minutes)
Download Audio
Free Registration Is Required
.
From Podium to Practice: Updates in HCV Treatment
Source: CCO Official Conference Coverage of the 2010 Annual Meeting of the American Association for the Study of Liver Diseases*
.
Capsule Summaries
After 12 Weeks of Telaprevir Treatment, PegIFN/RBV Can Be Shortened to 24 Weeks in HCV Genotype 1 Patients Achieving Extended RVR
SPRINT-2: Boceprevir Plus PegIFN/RBV for 24 Weeks Improves SVR Rates vs PegIFN/RBV in Treatment-Naive Patients With Genotype 1 HCV
BMS-790052 and BMS-650032 Coadministration Associated With Undetectable HCV RNA After 12 Weeks of Therapy With or Without PegIFN/RBV in Genotype 1 HCV Null Responders
ANA598 Improves HCV RNA Response to PegIFN/RBV in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection
Danoprevir Added to Standard PegIFN/RBV for 12 Weeks Associated With Rapid and Potent Viral Suppression in Patients With Genotype 1 HCV Infection
PROPEL: RG7128 Plus PegIFN alfa-2a/RBV Demonstrates High Rates of RVR and cEVR in Treatment-Naive Patients Infected With Genotype 1/4 HCV
Vaniprevir (MK-7009) With Peginterferon alfa-2a Plus Ribavirin Produces Higher RVR Rates in Treatment-Naive Genotype 1 HCV Patients
ADVANCE: Telaprevir Plus PegIFN/RBV Associated With Significant Increases in SVR in Treatment-Naive Patients With Genotype 1 HCV
RESPOND-2: High SVR Rates With Boceprevir and PegIFN/RBV Combination Therapy in Patients With Genotype 1 HCV Failing Previous PegIFN/RBV
MK-5172 Demonstrated Potent Antiviral Activity in Patients With Chronic Genotype 1 or 3 HCV Infection
Modeling Study Results Support IL-28B Genotype Stratification in HCV Clinical Trials of PegIFN/RBV Plus Direct-Acting Antivirals
Peginterferon Lambda Demonstrates Promising Early Virologic Response and Favorable Tolerability for the Treatment of HCV Infection
Higher Early Virologic Response With Telaprevir Plus PegIFN/RBV vs PegIFN/RBV or Telaprevir Monotherapy but Similar Rates of SVR in Treatment-Naive Patients With Genotype 4 HCV
.
From Podium to Practice: Updates in HBV Treatment
Source: CCO Official Conference Coverage of the 2010 Annual Meeting of the American Association for the Study of Liver Diseases*
.
Extending PegIFN alfa-2b From 24 to 48 Weeks Improves Responses in HBeAg-Positive Patients With Chronic Hepatitis B
Extending PegIFN alfa-2a From 48 to 96 Weeks Well Tolerated With Similar Incidence of Adverse Events in HBeAg-Negative Patients With Genotype D HBV
Alcohol Abuse and Diabetes Contribute to Severe Liver Disease Outcomes in Patients With Chronic Hepatitis B
Still In Progress Check CCO Website For Update A Prospective and Open-Label Study for the Efficacy and Safety of Telbivudine (Ltd) in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus (HBV) to the Infants (coming soon)
PegIFN 180 µg/week for 48 Weeks Provides Highest Seroconversion Rate vs Lower Dose and/or Shorter Treatment Duration in HBeAg-Positive HBV Infection
Still In Progress Check CCO Website For Update A Retrospective Study for Clinical Outcome of Caesarean Section on Perinatal Transmission of Hepatitis B Virus in Infants Born to HBeAg-Positive Mothers With Chronic Hepatitis B (CHB) (coming soon)
Tenofovir Provides Effective and Sustained Virologic Suppression in HBeAg-Positive HBV-Infected Patients Through 192 Weeks
.
No comments:
Post a Comment